Ayala Díaz, Rosa María Canal López, Alicia Castro Quismondo, Nerea Grande García, Carlos Martínez López, Joaquín Rueda Fernández, Daniel
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. [artículo] - British Journal of Haematology, 2012 - 158(4):555-8.
Formato Vancouver:
Martínez-López J, Castro N, Rueda D, Canal A, Grande C, Ayala R. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. Br J Haematol. 2012 Aug;158(4):555-8.
PMID: 22686329
Contiene 8 referencias
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. [artículo] - British Journal of Haematology, 2012 - 158(4):555-8.
Formato Vancouver:
Martínez-López J, Castro N, Rueda D, Canal A, Grande C, Ayala R. Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. Br J Haematol. 2012 Aug;158(4):555-8.
PMID: 22686329
Contiene 8 referencias
